ONCOLYTICS BIOTECH INC (ONCY): Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients

Oncolytics Biotech (ONCY) and Coherus Oncology (CHRS) agreed to test Pelareorep with LOQTORZI for anal carcinoma. Pelareorep is an immunotherapy agent, while LOQTORZI is an FDA-approved PD-1 inhibitor. The trial, set for 2027, will target patients who failed initial treatments. ONCY shares rose 7.81% to $0.41.

Oncolytics Biotech (ONCY) and Coherus Oncology agreed to evaluate pelareorep with LOQTORZI® (toripalimab-tpzi) in a clinical study for squamous cell anal carcinoma (SCAC). The study, set to begin in Q1 2027, will enroll patients who have progressed on standard treatments. Oncolytics aims to assess the combination's potential to enhance antitumor immune responses, with results possibly informing broader HPV-associated cancer strategies.

Oncolytics Biotech (ONCY) and Coherus Oncology (CHRS) agreed to study pelareorep with LOQTORZI for squamous cell anal carcinoma. The trial, set for 2027, targets patients who failed first-line treatments. Oncolytics aims to evaluate pelareorep's efficacy with a marketed PD-1 inhibitor. Both companies highlighted the unmet need in this indication.

Oncolytics Biotech presented data at the 68th ASH Annual Meeting showing pelareorep's immune-activating effects in relapsed/refractory multiple myeloma patients, including increased CD80 expression and CD8 effector memory T cells. Clinical responders showed greater immune activity than non-responders, according to the company.

Oncolytics Biotech (Nasdaq: ONCY) presented data at the ASH Annual Meeting showing pelareorep's potential to enhance immune responses in multiple myeloma patients. The Phase 1b/2 trial demonstrated improved antitumor activity and immune activation. Pelareorep is being evaluated in combination with other therapies for various cancers, with Fast Track designation from the FDA for colorectal, anal, and pancreatic cancers.

Oncolytics Biotech Inc. (ONCY) reported immune activation findings in multiple myeloma patients from a Phase 1b/2 trial, with data to be presented at ASH on December 12, 2026. The findings show antiviral immune activation and enhanced antitumor immunity with pelareorep, though further clinical results are needed for assessment.